Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Topline results from the MDD3001 study of seltorexant, an orexin-2 receptor antagonist, showed that the drug met all primary and secondary endpoints as a treatment for people with major depressive ...

In this manuscript, the role of orexin receptors in dopamine transmission is studied. It extends previous findings suggesting an interplay between these two systems in regulating behaviour by first ...

Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will be available for replay on demand Allschwil, Switzerland - January 15 ...

Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will ...

Dayvigo (lemborexant) is a dual orexin 1 and 2 receptor antagonist (DORA), a class which is billed as having fewer “morning-after” effects, such as drowsiness, memory problems and a risk of ...